Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma
| Autor: | Qiu Ym, Mao Q, Chen T, Xiang Zhang, Yi Sh, Jiannan Zhang, Ge Jw, Liu Xy, Xiong Wh, Li Sq |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Heterozygote Mdm2 snp309 Gastroenterology Polymorphism Single Nucleotide Risk Factors Internal medicine Glioma Epidemiology Genetics medicine Humans Genetic Predisposition to Disease Allele Molecular Biology Genetic Association Studies business.industry Brain Neoplasms Heterozygote advantage Proto-Oncogene Proteins c-mdm2 General Medicine Odds ratio medicine.disease Confidence interval Tumor Suppressor Protein p53 business Colorectal Neoplasms |
| Zdroj: | Genetics and molecular research : GMR. 11(4) |
| ISSN: | 1676-5680 |
| Popis: | Epidemiological studies of the association of variants p53 Arg72Pro and MDM2 single-nucleotide polymorphism 309 (SNP309) with glioma risk have produced inconsistent results. The aim of the current study was to evaluate the association of these 2 variants with glioma susceptibility using a meta-analysis approach. For p53 Arg72Pro, 10 case-control studies including 2587 glioma patients and 4061 unrelated controls were identified. The pooled odds ratios (ORs) for Arg/Pro heterozygotes and Pro/Pro homozygotes were 1.08 [95% confidence interval (95%CI) = 0.85-1.37] and 1.08 (95%CI = 0.85-1.36), respectively, when compared to Arg/Arg carriers. Under the dominant effect model, Pro allele carriers also showed no significantly elevated glioma risk (pooled OR = 1.11, 95%CI = 0.90-1.38), and similar results were found under the recessive-effect model (pooled OR = 1.17, 95%CI = 0.85-1.61). For variant MDM2 SNP309, 3 case-control studies including 606 cases and 309 controls were identified. A marginal association with glioma risk was found for heterozygous G/T carriers (pooled OR = 1.95, 95%CI = 1.00- 3.81), whereas homozygous G/G carriers showed an increased but not significantly elevated risk of glioma (pooled OR = 2.14, 95%CI = 0.71-6.45) compared with that of T/T homozygotes. We also found no significant association between the MDM2 SNP309 polymorphism and glioma risk (pooled OR = 1.86, 95%CI = 0.94-3.67 and pooled OR = 1.25, 95%CI = 0.62-2.56, respectively) under the dominant and recessive models. Taken together, the current data suggested that the 2 polymorphisms may not contribute to glioma susceptibility. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|